natgillin/translations-raw huggingface dataset:
(2) local adverse events associated with intravenous administration
(2) lokalni neželeni učinki povezani z intravensko uporabo.
(2)A 10.5 mg/kg loading dose is recommended on the first day of treatment with levetiracetam. (3)A 15 mg/kg loading dose is recommended on the first day of treatment with levetiracetam. (4)Following dialysis, a 3.5 to 7 mg/kg supplemental dose is recommended.
(2)Prvi dan zdravljenja z levetiracetamom je priporočljiv začetni odmerek 10,5 mg/kg. (3)Prvi dan zdravljenja z levetiracetamom je priporočljiv začetni odmerek 15 mg/kg. (4)Po dializi je priporočljiv dodatni odmerek od 3,5 do 7 mg/kg.
(2,000 IU/1.0ml)
0,5ml (2.000 i.e /1,0ml)
(2,400 mg single
(2.400 mg enkratni
(2,668 mg single
(2.668 mg enkratni
(2.06-5.16)
paritaprevirju je
(2.29-4.27)
aritaprevir/ri
(20 mg single
(20 mg enkratni
(20 ml).
10 odm erki (20 ml)
(20-120 mg once
(20-120 mg enkrat na
(20-150 mg once
(20-150 mg enkrat na
(20.2% vs 47.5%)
(20,2 % v prim. s
(20/120 mg tablet, 6 doses of 4
(20/120 mg tablete, 6 odmerkov po
(20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg once daily)
(20/120 mg tablete, 6 odmerkov po
(200 mg once
(200 mg enkrat na dan)
(200 mg once
fumarat (300 mg enkrat
(200 mg once daily
(200 mg enkrat na dan)
(200 mg q12h/600 mg once daily)
(200 mg q12h/600 mg enkrat na dan)
(200 mg single
(200 mg enkratni
(200 mg twice daily/400 mg once
(200 mg dvakrat na dan/400 mg enkrat
(2000 IU/ml)
(2000 i.e./ml)
(21.7; 49.6)
cepivo MenC-CRM
(23.4%; 44.1%)c
118 (83,9; 153,4)c
(25 mg once daily)/
(25 mg enkrat na
(25,000– 49,999/mm3)
(25.000– 49.999/mm3)
(250-270 microlitres) than the recommended dose (90 microlitres), a part of the volume contained in the syringe has to be discarded prior to the administration.
(250-270 mikrolitrov) od priporočenega odmerka (90 mikrolitrov), je treba del volumna v injekcijski brizgi zavreči pred aplikacijo zdravila.
(250/100 mg single dose/600 mg once daily)
(250/100 mg enkratni odmerek/600 mg
(250/100 mg single dose/600 mg once daily)
(250/100 mg enkratni odmerek/600 mg enkrat na dan)
(26.8-ne)
(26,8–no)
(26.8-ne)
30,52 (26,8-NO)
(26.9%)
(12,9–NE)
(28 weeks)
(28 tednov)
(2nd/3rd time)
(drugič/tretjič)
(3 micrograms)
(3 mikrogramov)
(3 years post vaccination)
(3 leta po cepljenju)
(3) A causal relationship between the medicinal product and the adverse event is at least a reasonable possibility.
(3) Vzročna povezava med zdravilom in neželenim dogodkom je vsaj možna.
(3) Briefly press
(3) Na kratko
(3) Briefly press and release red button.
(3) Na kratko pritisnite in spustite rdeči gumb.
(3) mean follow-up of 44 months post dose 1
(3 povprečno spremljanje 44 mesecev po 1. odmerku
(30 mL single dose/400 mg single
(enkratni odmerek 30 ml/enkratni
(30.8; 89.1)
Po provokaciji
(300 kg bodyweight)
(300 kg telesne mase)
(300 mg once
(300 mg enkrat na
(300 mg once
dan)/grazoprevir
(300 mg once daily)
(300 mg enkrat dnevno)
(300 mg once daily)/ elbasvir (50 mg once daily)
(300 mg enkrat na dan)/elbasvir (50 mg enkrat na dan)
(300 mg once daily/600 mg once
(300 mg enkrat na dan/600 mg enkrat
(300 mg once daily/600 mg once
(300 mg enkrat na dan/600 mg enkrat na
(300 mg twice daily*/100 mg
(300 mg dvakrat na dan*/100 mg
(300 mg twice daily*/100 mg twice
(300 mg dvakrat na dan*/100 mg
(300 mg twice daily*/100 mg twice
darunavir/ritonavir/efavirenz (300 mg dvakrat na dan*/100 mg
(300 mg)
10 kapsul (300 mg)
(300 micrograms)/day is recommended.
(300 mikrogramov)/dan, vsak drugi dan.
(300, 942)
V59P6E1
(3082.3, 3232.7)
mME§/ml
(35-42 years of age) (body weight greater than or equal to 50 kg)
(35-42 let starosti) (telesna masa 50 kg ali več)
(392/730)
virusnega bremena
(4 capsules/~6.5 ml twice daily
(4 kapsule/~6,5 ml dvakrat na dan,
(4 weeks)
(4 tedne)
(4 weeks)
1,5 mcg/kg/ teden (4 tedne)
(4 weeks)
1,5 mcg/kg/teden (4 tedne)
(4 – 6 in)
(4–6 palcev)
(4) Count slowly
(4) Počasi štejte
(4) p-value=0.0009 (5) in the ATP cohort VE was 100% (95% CI: 74.3-100; 0 versus 16 cases)
CAP, napoteni na rentgensko slikanje, 7,3 % (95 % IZ: 1,6; 12,6).
(4) Progression of pre-existing chronic myelomonocytic leukaemia with NRAS mutation.
(4) Napredovanje že prej obstoječe kronične mielomonocitne levkemije z mutacijo NRAS.
(4,000 IU/1.0ml)
0,5ml (4.000 i.e 1,0ml)
(4-[N-maleimidomethyl] cyclohexane-1-carboxylate).
Na DM1 je vezan kovalentno, preko stabilnega tioetrskega vezalca MCC (4-[N-maleimidometil] cikloheksan-1-karboksilat).
(40 mg once daily)/
(40 mg enkrat na
(40 mg single
(40 mg enkratni
(40 mg single dose/400 mg single
(enkratni odmerek 40 mg/enkratni
(400 mg once daily/100 mg once
(400 mg enkrat na dan/100 mg enkrat
(400 mg once daily/100 mg once
(400 mg enkrat na dan/100 mg enkrat na
(400 mg once daily/200 mg once
(400 mg enkrat na dan/200 mg enkrat na
(400 mg PO once
(400 mg peroralno enkrat
(400 mg single
(400 mg enkratni
(400 mg single dose/ - )
raltegravir/efavirenz (400 mg enkratni odmerek/ - )
(400 mg single dose/ -)
raltegravir/efavirenz (400 mg enkratni odmerek/ - )
(400 mg twice
(400 mg dvakrat na
(400 mg twice daily/300 mg once
vorikonazol/efavirenz
(400/100 mg twice daily/ 600 mg once daily)
enkrat na dan je treba odmerek
(400/100 mg twice daily/600 mg once daily)
(400/100 mg dvakrat na dan/600 mg
(40000 IU/ml)
(40000 i.e./ml)
(40mg/0.4ml)
uporaba
(40mg/0.8ml)
uporaba
(41, 98)
ACWY-P S
(424-1,497)
(25.–75. percentil)
(45.5-71.7)
aritaprevir/ri tonavir
(48th percentile).
Dvajset otrok (21 %) od skupaj
(4th time)
(četrtič)
(4x50)
CCID50/odmerek
(5 EL.U/ml)
(5 EL. e./ml)
(5 ml solvent) powder and solvent for solution for injection/infusion
VWF (5 ml vehikel) prašek in vehikel za raztopino za injiciranje/infundiranje
(5 years post vaccination)
(5 let po cepljenju)
(5 µg/ml)
(40 µg/ml)
(5) Check
(5) Preverite
(5) Progression of pre-existing pancreatic adenocarcinoma with KRAS mutation.
(5) Napredovanje že obstoječega adenokarcinoma trebušne slinavke z mutacijo KRAS.
(5.5 micrograms)
(5,5 mikrogramov)
(5.8, NE) (4.7, 7.9)
(5,8; NMO) (4,7; 7,9)
(50 mg once daily)
(50 mg enkrat na dan)
(50 mg once daily)
enkrat na dan)
(50 mg once daily)
odmerek)/elbasvir (50 mg enkrat na dan)
(50 mg once daily)/
(100 mg enkrat na dan)
(50 mg once daily)/
(50 mg enkrat na
(50 mg once daily)/
(50 mg enkrat na dan)/grazoprevir
(50 mg once daily)/
odmerek)/elbasvir (50 mg enkrat na
(50 mg once daily/600 mg once
(50 mg enkrat na dan/600 mg enkrat na
(50 mg single
(50 mg enkratni
(50 mg single
(50 mg enkratni odmerek)/grazoprevir
(50 mg single dose)
(50 mg enkratni
(50 mg single dose)
(50 mg enkratni odmerek)
(50 mg single dose)
enkratni odmerek)
(50,000– 99,999/mm3)
(50.000– 99.999/mm3)
(500 mg q12h/400 mg once daily)
(500 mg q12h/400 mg enkrat na dan)
(500 mg twice daily/600 mg once
(500 mg dvakrat na dan/600 mg enkrat
(500 mg twice daily/600 mg once
ritonavir/efavirenz (500 mg dvakrat na dan/600 mg enkrat na dan)
(500/125 mg twice daily/ 600 mg once daily)
na 500/125 mg dvakrat na dan.
(500/125 mg twice daily/600 mg
(400/100 mg dvakrat na dan/600 mg
(500/125 mg twice daily/600 mg once daily)
(500/125 mg dvakrat na dan/600 mg
(52 weeks)
(52 tednov)
(53%)
van der Heijde,
(6 Months of Complete Drug Withdrawal)
(6 mesecev popolne odtegnitve zdravila)
(6 to 24 hours for patients under the
vsakih 8 do 24 ur (6 do 24 ur za
(60.6, 69.7) (p<0.0001)
(60,6; 69,7) (p<0,0001)
(600 mg IV single
(600 mg enkratni
(600 mg once
(600 mg enkrat na
(600 mg once daily/600 mg once
(600 mg enkrat na dan/600 mg enkrat
(600 mg once daily/600 mg once
(600 mg enkrat na dan/600 mg enkrat na
(600 mg PO single
(600 mg peroralno enkrat
(600/100 mg twice daily) is used in
(600/100 mg dvakrat na dan)
(600/100 mg twice daily) is used in combination with elvitegravir, the
uporablja v kombinaciji z
(68-99)
Izboljšanje eGFR
(7.0-8.9 g/dl or any decrease
zmanjšanje
(7.1, 14.0) p<0.0001
(7,1; 14,0) p < 0,0001
(7.5 mmol/l) should be avoided; guidance for appropriate dose adjustments for when haemoglobin values exceeding 12 g/dl (7.5 mmol/l) are observed are described below.
Smernice za prilagoditev odmerka, če hemoglobin preseže 120 g/l (7,5 mmol/l), so navedene spodaj.
(7.8 %)
492 celic/mm3 (7,8 %)
(7.8 - 10.7)
N = 436
(70.2; 96.4)
serokonverzije
(72.9, 81.60) (p<0.0001)
(72,9; 81,6) (p<0,0001)
(75%)
odmerek (75 %)
(75.6% vs 53.9%) p=0.0003
p = 0,0003
(750 mg q8h/600 mg once daily)
(750 mg q8h/600 mg enkrat na dan)
(750 mg q8h/600 mg once daily)
400/100 mg dvakrat na dan
(750 mg/m² per day for 5 days) or cisplatin (100 mg/m² on day 1) and 5-fluorouracil (1000 mg/m² per day for 5 days).
(75 mg/m² 1. dan) in 5-fluorouracilom (F) (750 mg/m² na dan, 5 dni), bodisi cisplatin (100 mg/m² 1. dan) in 5-fluorouracil (1000 mg/m² na dan, 5 dni).
(8 mg/2 mg single
(8 mg/2 mg enkratni
(8 to 24 hours for patients under the
(8 do 24 ur za bolnike, mlajše
(8 to 24 hours for patients under the age
(8 do 24 ur za bolnike, mlajše
(8 to 24 hours for patients under the age
za bolnike, mlajše od 6 let)
(8-24 mg/2-6 mg
(8-24 mg/2-6 mg enkrat
(8.4 - 11.9)
N = 411
(800 mg q8h/200 mg once daily)
(800 mg q8h/200 mg enkrat na dan)
(800-1,200 mg/day based on weight) plus interferon alfa-2b (3 MIU TIW).
1.200 mg/dan glede na telesno maso) in interferon alfa-2b (3 milijone i.e. trikrat na teden).
(86, 100)
Čas
(9.0-9.9 g/dl or any decrease
(90-99 g/l ali kakršnokoli
(90 % CI 44-131 %)
Narkotični analgetiki
(90% CI 32%-59%)
(90-% interval zaupanja; 32 %-59 %)
(95 % CI)
(95% IZ)
(95 % CI)
(95-% interval zaupanja)
(95 % CI)
P al
(95 % CI)
Razlika† (95 % IZ)
(95 % Confidence interval [CI])
(95 % interval zaupanja [IZ])
(95 %CI)
(95-% IZ)
(95% C.I.c)
(95-odstotni IZ c)
(95% CI of
(95% IZ
(95% CI)
(95 % interval zaupanja)
(95% CI)
(n = 813)
(95% CI)
10,3 (9,8–11,2)
(95% CI)
95-odstotni IZ
(95% CI)
indeks (95
(95% CI)
meseci
(95% CI)
odstotni IZ]
(95% CI)
placebomc
(95% CI) for ORRc
95-% interval zaupanja za ORRc
(95% CI) mMU§/mL
(95 % IZ) mME§/ml
(95% CI: 51.3-84.2%)
21/31 = 67,7 % (95-odstotni IZ: 51,3-84,2 %)
(95% CI: 68.2-83.5%)
91/120 = 75,8 % (95-odstotni IZ: 68,2-83,5 %)
(95% CIc)
(95 % IZc)
(95% confidence interval)
zaupanja)
(95% Confidence Intervalb)
X (95% interval zaupanjab)
(95%CI)
15,7
(97.5% CI)
HRa (97,5-% IZ)
(< 0.001)
> 54 tednov (< 0,001)
(< 25,000/mm3)
(< 25.000/mm3)
(>600,000 IU/ml)
(>600.000 i.e./ml
(A brief form of these instructions is included on the back of the Analysis Request Form)
(skrajšana verzija teh navodil se nahaja na zadnji strani obrazca za naročilo analize)
(A ml Busilvex) x (10) = B ml of diluent
(A ml zdravila Busilvex) x (10) = B ml redčila
(a) Cimzia administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4
(a) Odmerjanje zdravila Cimzia vsaka 2 tedna po jemanju polnilnega odmerka 400 mg na začetku zdravljenja, drugi in četrti teden
(a) Cimzia all dosing regimen = data from Cimzia 200 mg administered every 2 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 plus Cimzia 400 mg administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 (b) Results are from the randomized set (c) Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.
(a) Cimzia vsi režimi odmerjanja = rezultati pri odmerjanju zdravila Cimzia 200 mg vsaka 2 tedna po jemanju polnilnega odmerka 400 mg na začetku zdravljenja, drugi in četrti teden ter rezultati pri odmerjanju zdravila Cimzia 400 mg vsake 4 tedne po jemanju polnilnega odmerka na začetku zdravljenja, drugi in četrti teden (b) Rezultati iz naključnega vzorca (c) Waldove p-vrednosti so citirane za primerjavo zdravljenj.
(a) Daily targeted dose, (b) Mean (SD), (c) analysis population (mITT); MMRM model for change from Baseline to Endpoint includes treatment, region, and visit as fixed effects, and baseline value as a covariate; (d) target dose of 100 mg/day; (e) analysis population (mITT); data are presented as the number (percentage) of patients in each group meeting the responder definition (f) chi-square test of the odds ratio of the treatment groups compared to placebo using a logistic regression model, with fixed effects for treatment and country.
(a) Dnevni ciljni odmerek, (b) povprečje (SD), (c) populacija za analizo (mITT); model MMRM za spremembo od izhodiščne vrednosti do končne točke vključuje zdravljenje, regijo in obisk kot fiksne učinke ter izhodiščno vrednost kot sospremenljivko; (d) ciljni odmerek 100 mg/dan; (e) populacija za analizo (mITT); podatki so predstavljeni kot številka (odstotek) bolnikov v vsaki skupini, ki ustreza definiciji bolnika, ki se odziva na zdravljenje; (f) test hi-kvadrat razmerja obetov v skupinah zdravljenja v primerjavi s placebom z uporabo modela logistične regresije, s fiksnimi učinki za zdravljenje in državo.
(a) Patients were not censored at the time of cross-over
(a) Bolniki niso bili krnjeni ob času prehoda.
(a) The intensity of clinical adverse events graded by the Common Terminology Criteria for Adverse Events v4.0 (CTC-AE).
(a)Izrazitost kliničnih neželenih dogodkov je ocenjena po CTC-AE (Common Terminology Criteria for Adverse Events) v 4.0.
(A-Responsive Patients)
ŠTUDIJA (bolniki, dovzetni za A)
(Aclar/PVC/alu) in a card blister
pretisni omot
(acute) renal failure (severe kidney disorder)
(akutna) ledvična odpoved (huda bolezen ledvic)
(additional test to
(dodatna preiskava za
(affects 1 to 10 users in 1,000)
(pojavijo se pri do 1 do 10 od 1.000 bolnikov)
(affects 1 to 10 users in 100)
(pojavijo se pri do 1 do 10 od 100 bolnikov)
(affects more than 1 user in 10)
(pojavijo se pri več kot 1 od 10 bolnikov)
(Al/Aclar/PVAc/PVC)
EU/1/04/293/003
(Al/Aclar/PVAc/PVC)
EU/1/04/293/004
(Al/Aclar/PVAc/PVC)
EU/1/04/293/006
(Al/Aclar/PVAc/PVC)
EU/1/04/293/007
(ALT, AST), especially in early treatment (see section 4.4)
začetku zdravljenja (glejte poglavje 4.4)
(alu/alu)
uporaba
(alu/alu) (peelable)
(z odstranjivo folijo)
(Amprenavir without
(amprenavir brez ritonavirja)
(as given in a
odmerek
(at dose 400 mg)
(pri odmerku 400 mg)
(at dose 800 mg)
(ob odmerku 800 mg)
(at least 1 in 10 people are affected)
(pojavijo se pri vsaj 1 od 10 bolnikov)
(atazanavir 300 mg once daily with
(atazanavir 300 mg enkrat na dan z
(atazanavir 400 mg once daily,
(atazanavir 400 mg enkrat na dan,
(atazanavir 400 mg single dose)
(atazanavir 400 mg
(atorvastatin 40 mg single dose +
(atorvastatin 40 mg enkratni odmerek + zdravilo Victrelis 800 mg
(attached as concertina label directly to the immediate package)
(zloženo v obliki harmonike in pripeto neposredno na stično ovojnino)
(attached as concertina label directly to the immediate package)
(zloženo v obliki harmonike in pripeto neposredno na stično pakiranje)
(b) Cimzia administered every 4 weeks preceded by a loading dose of 400 mg at Weeks 0, 2 and 4 (c) In subjects with at least 3% psoriasis BSA at Baseline
(b) Odmerjanje zdravila Cimzia vsake 4 tedne po jemanju polnilnega odmerka 400 mg na začetku zdravljenja, drugi in četrti teden (c) Bolniki, ki so imeli v izhodišču najmanj 3 % telesne površine prizadete s psoriazo
(BCR-ABL ≤0.01% on the International Scale), %
(BCR-ABL ≤0,01 % na mednarodni lestvici),
(Best Response Rate)
največji delež odzivov)
(bisphosphonate class adverse reaction)
(neželeni učinek skupine bisfosfonatov)
(BLISTER/ 7, 14, 28 or 84 tablets)
(PRETISNI OMOT / 7, 14, 28 ali 84 tablet)
(BLISTER/ 7, 14, 28 or 84 tablets)
(PRETISNI OMOT/ 7, 14, 28 ali 84 tablet)
(blood uric acid increased)
(povečane ravni sečne kisline v krvi)
(blood uric acid increased)
laktatdehidrogen
(BOTTLE LABEL)
(NALEPKA NA PLASTENKI)
(Box of 3 pipettes)
(Škatla s 3 merilnimi kapalkami)
(boxes of 7, 14, 28 or 84 tablets)
(Škatle po 7, 14, 28 ali 84 tablet)
(buffered tablets) and stavudine.
didanozinom (pufrane tablete) in
(buprenorphine/naloxone 8/2 –
(buprenorfin/nalokson 8/2 – 24/6 mg
(calculated using the child’s height and weight) over 1.4 m2.
(izračunano na podlagi otrokove višine in telesne mase).
(Card of 1 pipette)
(Omot z 1 merilno kapalko)
(Carton 250 IU/600 IU)
(Škatla 250 i.e./ 600 i.e.)
(CARTON OF MULTIPACK (12x 1 SINGLE PACKS) (INCLUDING BLUE BOX)
ŠKATLA Z VEČ PAKIRANJI (12 X 1 POSAMEZNO PAKIRANJE) (VKLJUČUJE BLUEBOX)
(CARTON OF MULTIPACK (14x 1 SINGLE PACKS) (INCLUDING BLUE BOX)
ŠKATLA Z VEČ PAKIRANJI (14 X 1 POSAMEZNO PAKIRANJE) (VKLJUČUJE BLUEBOX)
(CARTON OF MULTIPACK (15x 1 SINGLE PACKS) (INCLUDING BLUE BOX)
ŠKATLA Z VEČ PAKIRANJI (15 X 1 POSAMEZNO PAKIRANJE) (VKLJUČUJE BLUEBOX)
(CLcr < 30 mL/min, requiring dialysis)
(CLcr < 30 ml/min, dializa je potrebna)
(clear)
(čisto)
(clinical response at both week 8 and week 30)a
Trajnejši odziv (klinični odziv tako v 8. tednu kot v 30. tednu)a
(clopidogrel: 9.6%; placebo: 6.6%), 1-3 months (clopidogrel: 4.5%; placebo: 2.3%), 3-6 months (clopidogrel: 3.8%; placebo: 1.6%), 6-9 months (clopidogrel: 3.2%; placebo: 1.5%), 9-12 months (clopidogrel: 1.9%; placebo: 1.0%).
Tveganje za krvavitve (življenje ogrožajoče, velike, manjše, druge) se je zmanjševalo med preizkušanjem: 0-1 meseca (klopidogrel: 9,6%%; placebo: 6,6%%), 1-3 mesecev (klopidogrel: 4,5%%; placebo: 2,3%%), 3–6 mesecev (klopidogrel: 3,8%%; placebo: 1,6%%), 6–9 mesecev (klopidogrel: 3,2%%; placebo: 1,5%%), 9–12 mesecev (klopidogrel: 1,9%%; placebo: 1%%).
(cobicistat 150 mg once daily)
enkratni odmerek
(Cochran-Mantel-Haenszel) test stratified by the prior treatment regimen (EFV/FTC/TDF, FTC/TDF plus boosted atazanavir, or E/C/F/TDF).
(Cochran-Mantel-Haenszel) stratificiran po predhodnem režimu zdravljenja (EFV/FTC/TDF, FTC/TDF z ojačanim atazanavirjem ali E/C/F/TDF).
(combination of mechanisms including
(kombinacija mehanizmov vključno z
(combined atorvastatin groups)
(združeni podatki skupin z atorvastatinom)
(combined rosuvastatin, simvastatin, & atorvastatin groups)
(združeni podatki skupin z rosuvastatinom, simvastatinom in atorvastatinom)
(combined)
(kombinirano)
(common - may affect up to 1 in 10 people)
(pogosti - pojavijo se lahko pri največ 1 od 10 bolnikov)
(common - may affect up to 1 in 10 people)
(pogosti – pojavijo se lahko pri največ 1 od 10 bolnikov)
(Common - may affect up to 1 in 10 people) lung infection (e.g. pneumonia, bronchitis)
(Pogosti – pojavijo se lahko pri največ 1 od 10 bolnikov) okužba pljuč (npr. pljučnica, bronhitis)
(Common - may affect up to 1 in 10 people) severe wide-spread rash.
(Pogosti – pojavijo se lahko pri največ 1 od 10 bolnikov) resen razširjen izpuščaj
(competitive inhibition of
(kompetitivno zaviranje
(competitive inhibition of oxidative
(kompetitivno zaviranje
(Complex binding to
(Tvori kompleks s
(concent
promet
(concentratio
pakiranja
(concentration)
pakiranja
(concentration)
promet
(Confirmed3) [95% CI]
(potrjen3) [95 % interval zaupanja]
(Confirmed3) [95% CI]
(potrjen3) [95 %-ni interval zaupanja]
(Contains blue box)
(vsebuje »blue box«)
(creatinine clearance estimated using Schwartz formula)
(kreatininski očistek je bil ocenjen po Schwartzovi formuli)
(cyclosporine 100 mg single dose +
(ciklosporin 100 mg enkratni
(CYP2C9 substrate)
1 mcg/kg/ teden
(CYP2D6 and
1,33
(CYP2D6 and/or CYP3A inhibition).
(zaviranje CYP2D6 in/ali CYP3A)
(CYP2D6 inhibition and/or P-gp)
(zaviranje CYP26D in/ali P-gp)
(CYP2D6 substrate)
dezipramin (substrat CYP2D6)
(CYP3A and OATPB1
(zaviranje CYP3A in OATPB1)
(CYP3A and/ or P-glycoprotein inhibition)
(zaviranje CYP3A in/ali P-gp)
(CYP3A and/or CYP2D6 inhibition)
(zaviranje CYP3A)
(CYP3A and/or P-gp inhibition)
(zaviranje CYP3A4 in/ali P-gp)
(CYP3A inhibition -
(zaviranje CYP3A
(CYP3A inhibition - effect on
(zaviranje CYP3A – učinek na
(CYP3A inhibition and/or P-gp
(zaviranje CYP3A in/ali
(CYP3A inhibition – effect on
(zaviranje CYP3A – učinek na
(CYP3A inhibition – effect on
(zaviranje CYP3A – učinek na maravirok)
(CYP3A inhibition)
proti raku.
(CYP3A or P-gp induction)
(indukcija CYP3A in P-gp)
(CYP3A4 and CYP2B6 induction)
(indukcija CYP3A4 in
(CYP3A4 enzyme induction)
(šibko do zmerno zaviranje CYP3A4)
(CYP3A4 enzyme inhibition)
(zaviranje CYP3A4)
(CYP3A4 induction by St. John’s wort)
(indukcija CYP3A4 s šentjanževko)
(CYP3A4 inhibition by
(inhibicija CYP3A4 z FPV/RTV)
(CYP3A4 inhibition)
Uporabljati s previdnostjo.
(CYP3A4 substrate)
midazolam (substrat CYP3A4)
(Day 1) then 100 mg QD
na dan (1. dan), nato 100 mg
(decrease in itraconazole
(zmanjšanje koncentracij
(deep partial and full thickness)
(dermalne in subdermalne)
(Do not inject within a 5-cm area around the navel.)
(Ne injicirajte v 5-centimetrski predel okrog popka.)
(double-blind)
(dvojno slepa)
(drospirenone - CYP3A
CYP3A4)
(drug) hypersensitivity
preobčutljivost (na zdravilo)
(DXM)
rifampicin1
(e.g. azithromycin) may be
klaritromicinu (npr. azitromicina).
(e.g. lipohypertro
injiciranja (npr.
(e.g., phenprocoumon,
ta fenprokumon in
(efavirenz 600 mg daily + Victrelis
(efavirenz 600 mg dnevno + zdravilo
(effect on P-gp transport in the
(učinek na prenos s pomočjo P- gp v črevesju)
(EPP*: N = 937; ITT**: N= 1017)
(EPP*: n = 967; ITT**: n = 1.017)
(EPP*: N=937; ITT**: N=1017)
(EPP*: n = 937; ITT**: n = 1.017)
(EPP*: N=937; ITT**: N=1017)
(EPP*: N=937; ITT**: N=1.017)
(EPP*: N=967; ITT**: N=1017)
(EPP*: n = 967; ITT**: n = 1.017)
(EPP*: N=967; ITT**: N=1017)
(EPP*: N=967; ITT**: N=1.017)
(escitalopram 10 mg single dose +
(escitalopram 10 mg enkratni odmerek + zdravilo Victrelis 800 mg
(etravirine 200 mg every 12 hours +
(etravirin 200 mg vsakih 12 ur +
(Exon2_4dup?)
NEZNANO (Exon2_4dup?)
(Eylea 2 mg every 8 weeks following 3 initial monthly doses) (N = 607)
8 tednov po 3 začetnih mesečnih odmerkih) (N = 607)
(F205 strain)
EU/2/01/029/002 Eurican
(F205 strain)
EU/2/01/029/003 Eurican
(Facial) flushing
zardevanje (obraza)
(for 10 days)
Odmerek za preprečevanje (za 10 dni)
(for 5 days)
Odmerek za zdravljenje (za 5 dni)
(For LIPROLOG suspensions cloudy insulins only)
(samo za motne insuline v suspenziji LIPROLOG)
(For Poland only)
(samo za Poljsko)
(frequency cannot be estimated from the available data)
(pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
(frequency cannot be estimated from the available data)
(pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
(further reduction to 15 mg if 30 mg are not well tolerated)
(nadaljnje zmanjšanje na 15 mg, če bolnik 30 mg ne prenaša dobro)
(G3/4: 0.6%)
venska bolezen (S3/4: 0,6 %)
(glass)
(steklo)
(glass)
brizga
(glass)
brizga (steklena)
(glass)
brizga (steklo)
(glass)
EU/1/00/152/021
(glass)
injekcijska
(glass)
injekcijska brizga
(glass)
viala (steklo)
(glass)
vsebina
(glass)
Vsebnost
(glass) ampoule of 1,000 doses of vaccine, 5-ampoule carrier.
(steklena) ampula s 1,000 odmerki cepiva, nosilec s 5 ampulami.
(glass) ampoule of 2,000 doses of vaccine, 4-ampoule carrier.
(steklena) ampula z 2,000 odmerki cepiva, nosilec s 4 ampulami.
(glass) ampoule of 2,000 doses of vaccine, 4-ampoule carrier.
(steklena) ampula z 2.000 odmerki cepiva, nosilec s 4 ampulami.
(glass) in pre- filled pen
1 napolnjen injekcijski peresnik
(glass) in pre-filled pen (OptiSet) cartridge
Vložek (steklen) v
(glass) in pre-filled pen (OptiSet) cartridge
Vložek (steklen) za
(glass) in pre-filled pen (SoloStar) cartridge
Vložek (steklen) v
(glass) single dose vial
enoodmerna
(glass) Solvent: vial
Vehikla: viala (stekleni ka
(glass) vial (glass)
viala (steklo)
(glass) with needle-trap
(steklena) z
(glass);
(steklo)
(glass); solvent:
vehikel: ampula
(glass); solvent: vial
(steklo); vehikel: viala
(Graded per Table 1)
(opredeljeno po razpredelnici 1)
(HCV-RNA Results†)
(HCV-RNA
(Hypericum Perforatum)
(Hypericum
(hypotension,
(hipotenzija,
(ICU) or similar setting which
izpostavljenosti rifabutinu, kar
(ICU) or similar setting, which
je treba odmerjati na oddelku
(If the sample tube remains open for more than 30 seconds, the test result might be falsified.)
(Če ostane odprta več kot 30 sekund, bo izid testa morda napačen.)
(immediate
išias,
(immunogenicity report)
do konca 4. četrtletja 2016 (poročilo o imunogenosti)
(in remission at both week 8 and week 30)a
Trajnejša remisija (remisija tako v 8. tednu kot v
(in two divided doses)
(v dveh deljenih odmerkih)
(incl.
glavobol
(incl.
halucinacijami,
(including
(vključno s
(including
(vključno z
(including
angioedem, z
(including
Distonija (vključno
(including
Distonija (vključno z
(including
infundiranja (vključno s
(including allergic
bruhanje
(including cysts and
(vključno s cistami in
(including cysts and polyps)
Benigne, maligne in neopredelje ne novotvorbe (vključno s cistami in polipi)
(including hematoma,
krvavitvijo), zatrdlina na